Cargando…
Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing
BACKGROUND: The aim of this study was to evaluate the cost-effectiveness of CRC screening strategies from the healthcare service provider perspective based on Chinese population. METHODS: A Markov model was constructed to compare the cost-effectiveness of recommended screening strategies including a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608156/ https://www.ncbi.nlm.nih.gov/pubmed/26471036 http://dx.doi.org/10.1186/s12885-015-1730-y |
_version_ | 1782395621078990848 |
---|---|
author | Wong, Carlos KH Lam, Cindy LK Wan, YF Fong, Daniel YT |
author_facet | Wong, Carlos KH Lam, Cindy LK Wan, YF Fong, Daniel YT |
author_sort | Wong, Carlos KH |
collection | PubMed |
description | BACKGROUND: The aim of this study was to evaluate the cost-effectiveness of CRC screening strategies from the healthcare service provider perspective based on Chinese population. METHODS: A Markov model was constructed to compare the cost-effectiveness of recommended screening strategies including annual/biennial guaiac fecal occult blood testing (G-FOBT), annual/biennial immunologic FOBT (I-FOBT), and colonoscopy every 10 years in Chinese aged 50 year over a 25-year period. External validity of model was tested against data retrieved from published randomized controlled trials of G-FOBT. Recourse use data collected from Chinese subjects among staging of colorectal neoplasm were combined with published unit cost data ($USD in 2009 price values) to estimate a stage-specific cost per patient. Quality-adjusted life-years (QALYs) were quantified based on the stage duration and SF-6D preference-based value of each stage. The cost-effectiveness outcome was the incremental cost-effectiveness ratio (ICER) represented by costs per life-years (LY) and costs per QALYs gained. RESULTS: In base-case scenario, the non-dominated strategies were annual and biennial I-FOBT. Compared with no screening, the ICER presented $20,542/LYs and $3155/QALYs gained for annual I-FOBT, and $19,838/LYs gained and $2976/QALYs gained for biennial I-FOBT. The optimal screening strategy was annual I-FOBT that attained the highest ICER at the threshold of $50,000 per LYs or QALYs gained. CONCLUSION: The Markov model informed the health policymakers that I-FOBT every year may be the most effective and cost-effective CRC screening strategy among recommended screening strategies, depending on the willingness-to-pay of mass screening for Chinese population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02038283 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1730-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4608156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46081562015-10-17 Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing Wong, Carlos KH Lam, Cindy LK Wan, YF Fong, Daniel YT BMC Cancer Research Article BACKGROUND: The aim of this study was to evaluate the cost-effectiveness of CRC screening strategies from the healthcare service provider perspective based on Chinese population. METHODS: A Markov model was constructed to compare the cost-effectiveness of recommended screening strategies including annual/biennial guaiac fecal occult blood testing (G-FOBT), annual/biennial immunologic FOBT (I-FOBT), and colonoscopy every 10 years in Chinese aged 50 year over a 25-year period. External validity of model was tested against data retrieved from published randomized controlled trials of G-FOBT. Recourse use data collected from Chinese subjects among staging of colorectal neoplasm were combined with published unit cost data ($USD in 2009 price values) to estimate a stage-specific cost per patient. Quality-adjusted life-years (QALYs) were quantified based on the stage duration and SF-6D preference-based value of each stage. The cost-effectiveness outcome was the incremental cost-effectiveness ratio (ICER) represented by costs per life-years (LY) and costs per QALYs gained. RESULTS: In base-case scenario, the non-dominated strategies were annual and biennial I-FOBT. Compared with no screening, the ICER presented $20,542/LYs and $3155/QALYs gained for annual I-FOBT, and $19,838/LYs gained and $2976/QALYs gained for biennial I-FOBT. The optimal screening strategy was annual I-FOBT that attained the highest ICER at the threshold of $50,000 per LYs or QALYs gained. CONCLUSION: The Markov model informed the health policymakers that I-FOBT every year may be the most effective and cost-effective CRC screening strategy among recommended screening strategies, depending on the willingness-to-pay of mass screening for Chinese population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02038283 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1730-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-15 /pmc/articles/PMC4608156/ /pubmed/26471036 http://dx.doi.org/10.1186/s12885-015-1730-y Text en © Wong et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wong, Carlos KH Lam, Cindy LK Wan, YF Fong, Daniel YT Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing |
title | Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing |
title_full | Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing |
title_fullStr | Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing |
title_full_unstemmed | Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing |
title_short | Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing |
title_sort | cost-effectiveness simulation and analysis of colorectal cancer screening in hong kong chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608156/ https://www.ncbi.nlm.nih.gov/pubmed/26471036 http://dx.doi.org/10.1186/s12885-015-1730-y |
work_keys_str_mv | AT wongcarloskh costeffectivenesssimulationandanalysisofcolorectalcancerscreeninginhongkongchinesepopulationcomparisonamongstcolonoscopyguaiacandimmunologicfecaloccultbloodtesting AT lamcindylk costeffectivenesssimulationandanalysisofcolorectalcancerscreeninginhongkongchinesepopulationcomparisonamongstcolonoscopyguaiacandimmunologicfecaloccultbloodtesting AT wanyf costeffectivenesssimulationandanalysisofcolorectalcancerscreeninginhongkongchinesepopulationcomparisonamongstcolonoscopyguaiacandimmunologicfecaloccultbloodtesting AT fongdanielyt costeffectivenesssimulationandanalysisofcolorectalcancerscreeninginhongkongchinesepopulationcomparisonamongstcolonoscopyguaiacandimmunologicfecaloccultbloodtesting |